Drug Trial Radar · NCT04776746
Open-Label Extension Study of Trofinetide for Rett Syndrome
Last checked: Nov 19, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
77
Actual
Start
Nov 8, 2020
Primary completion
Jun 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 5 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the safety and tolerability of continued long-term treatment with oral trofinetide in girls and women with Rett syndrome
Conditions
- Rett Syndrome
Interventions
trofinetideDrug
Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With Treatment-emergent Adverse Events (TEAEs), With Serious Adverse Events (SAEs), and With Withdrawals Due to AEsTime frame: Mean study drug exposure was 426 days, corresponding to 1.2 years
- Number (%) of Patients With Potentially Clinically Important Changes in ECG Post-baselineTime frame: Mean study drug exposure was 426 days, corresponding to 1.2 years
- Number (%) of Patients With Potentially Clinically Important Changes in Vital Signs Post-baselineTime frame: Mean study drug exposure was 426 days, corresponding to 1.2 years
- Number (%) of Patients With Potentially Clinically Important Changes in Body Weight Post-baselineTime frame: Mean study drug exposure was 426 days, corresponding to 1.2 years
- Number (%) of Patients With Potentially Clinically Important Changes in Laboratory Parameters Post-baselineTime frame: Mean study drug exposure was 426 days, corresponding to 1.2 years
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Translational Genomics Research Institute (TGen)
Phoenix, Arizona
University of California, San Diego
La Jolla, California
UC Davis MIND Institute
Sacramento, California
Children's Hospital Colorado Aurora
Aurora, Colorado
University of South Florida
Tampa, Florida
Emory Genetics Clinical Trial Center
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
Kennedy Krieger Institute, John Hopkins School of Medicine
Baltimore, Maryland
Boston Children's Hospital Harvard Medical School
Boston, Massachusetts
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota
Washington University School of Medicine
St Louis, Missouri
Montefiore Medical Center
The Bronx, New York
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Greenwood Genetic Center
Greenwood, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Children's Hospital
Houston, Texas
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.